Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: SEC24C

Gene summary for SEC24C

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

SEC24C

Gene ID

9632

Gene nameSEC24 homolog C, COPII coat complex component
Gene AliasSEC24C
Cytomap10q22.2
Gene Typeprotein-coding
GO ID

GO:0001701

UniProtAcc

A0A024QZM6


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
9632SEC24CLZE20THumanEsophagusESCC4.80e-023.98e-020.0662
9632SEC24CLZE22THumanEsophagusESCC2.91e-052.83e-010.068
9632SEC24CLZE24THumanEsophagusESCC6.68e-164.16e-010.0596
9632SEC24CP1T-EHumanEsophagusESCC1.62e-042.16e-010.0875
9632SEC24CP2T-EHumanEsophagusESCC2.71e-162.74e-010.1177
9632SEC24CP4T-EHumanEsophagusESCC3.71e-142.30e-010.1323
9632SEC24CP5T-EHumanEsophagusESCC6.11e-129.56e-020.1327
9632SEC24CP8T-EHumanEsophagusESCC2.69e-142.41e-010.0889
9632SEC24CP10T-EHumanEsophagusESCC1.37e-112.03e-010.116
9632SEC24CP11T-EHumanEsophagusESCC5.04e-071.86e-010.1426
9632SEC24CP12T-EHumanEsophagusESCC9.93e-153.17e-010.1122
9632SEC24CP15T-EHumanEsophagusESCC6.64e-162.82e-010.1149
9632SEC24CP16T-EHumanEsophagusESCC7.87e-152.89e-010.1153
9632SEC24CP17T-EHumanEsophagusESCC2.63e-083.08e-010.1278
9632SEC24CP19T-EHumanEsophagusESCC2.05e-063.84e-010.1662
9632SEC24CP20T-EHumanEsophagusESCC1.31e-092.28e-010.1124
9632SEC24CP21T-EHumanEsophagusESCC5.02e-204.37e-010.1617
9632SEC24CP22T-EHumanEsophagusESCC7.41e-061.02e-010.1236
9632SEC24CP23T-EHumanEsophagusESCC3.34e-153.09e-010.108
9632SEC24CP24T-EHumanEsophagusESCC1.75e-132.56e-010.1287
Page: 1 2 3 4 5 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:004819318EsophagusESCCGolgi vesicle transport231/8552296/187231.82e-309.63e-28231
GO:001605014EsophagusESCCvesicle organization211/8552300/187232.85e-182.87e-16211
GO:000170119EsophagusESCCin utero embryonic development243/8552367/187231.00e-156.86e-14243
GO:000688815EsophagusESCCendoplasmic reticulum to Golgi vesicle-mediated transport102/8552130/187231.73e-149.22e-13102
GO:0006900111EsophagusESCCvesicle budding from membrane54/855261/187232.66e-121.07e-1054
GO:009011414EsophagusESCCCOPII-coated vesicle budding27/855229/187238.09e-081.39e-0627
GO:00901104EsophagusESCCCOPII-coated vesicle cargo loading14/855215/187231.47e-049.85e-0414
GO:00354595EsophagusESCCvesicle cargo loading19/855227/187238.35e-032.95e-0219
GO:004819321LiverHCCGolgi vesicle transport217/7958296/187232.58e-271.02e-24217
GO:000688821LiverHCCendoplasmic reticulum to Golgi vesicle-mediated transport100/7958130/187231.15e-158.67e-14100
GO:001605021LiverHCCvesicle organization194/7958300/187235.58e-153.97e-13194
GO:000690021LiverHCCvesicle budding from membrane53/795861/187237.38e-133.80e-1153
GO:00901142LiverHCCCOPII-coated vesicle budding27/795829/187231.28e-083.14e-0727
GO:000170111LiverHCCin utero embryonic development204/7958367/187232.44e-074.30e-06204
GO:00901102LiverHCCCOPII-coated vesicle cargo loading14/795815/187235.65e-055.26e-0414
GO:003545921LiverHCCvesicle cargo loading19/795827/187233.18e-031.47e-0219
GO:004819315Oral cavityOSCCGolgi vesicle transport209/7305296/187231.39e-286.30e-26209
GO:00160508Oral cavityOSCCvesicle organization189/7305300/187232.40e-172.14e-15189
GO:00068888Oral cavityOSCCendoplasmic reticulum to Golgi vesicle-mediated transport97/7305130/187231.42e-161.15e-1497
GO:000170116Oral cavityOSCCin utero embryonic development207/7305367/187237.92e-122.95e-10207
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04141211EsophagusESCCProtein processing in endoplasmic reticulum147/4205174/84653.29e-221.10e-195.64e-20147
hsa05130211EsophagusESCCPathogenic Escherichia coli infection142/4205197/84658.21e-111.06e-095.42e-10142
hsa04141310EsophagusESCCProtein processing in endoplasmic reticulum147/4205174/84653.29e-221.10e-195.64e-20147
hsa05130310EsophagusESCCPathogenic Escherichia coli infection142/4205197/84658.21e-111.06e-095.42e-10142
hsa0414122LiverHCCProtein processing in endoplasmic reticulum146/4020174/84657.34e-242.46e-211.37e-21146
hsa0513042LiverHCCPathogenic Escherichia coli infection129/4020197/84652.02e-072.50e-061.39e-06129
hsa0414132LiverHCCProtein processing in endoplasmic reticulum146/4020174/84657.34e-242.46e-211.37e-21146
hsa0513052LiverHCCPathogenic Escherichia coli infection129/4020197/84652.02e-072.50e-061.39e-06129
hsa0414130Oral cavityOSCCProtein processing in endoplasmic reticulum143/3704174/84656.82e-262.28e-231.16e-23143
hsa0513030Oral cavityOSCCPathogenic Escherichia coli infection129/3704197/84654.32e-105.17e-092.63e-09129
hsa04141113Oral cavityOSCCProtein processing in endoplasmic reticulum143/3704174/84656.82e-262.28e-231.16e-23143
hsa05130114Oral cavityOSCCPathogenic Escherichia coli infection129/3704197/84654.32e-105.17e-092.63e-09129
hsa04141210Oral cavityLPProtein processing in endoplasmic reticulum113/2418174/84658.74e-245.82e-223.76e-22113
hsa05130210Oral cavityLPPathogenic Escherichia coli infection87/2418197/84651.71e-061.78e-051.15e-0587
hsa0414138Oral cavityLPProtein processing in endoplasmic reticulum113/2418174/84658.74e-245.82e-223.76e-22113
hsa0513038Oral cavityLPPathogenic Escherichia coli infection87/2418197/84651.71e-061.78e-051.15e-0587
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
SEC24CSNVMissense_Mutationrs755761928c.614N>Tp.Ser205Phep.S205FP53992protein_codingdeleterious(0.04)benign(0.05)TCGA-A8-A08H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
SEC24CSNVMissense_Mutationc.1521N>Cp.Met507Ilep.M507IP53992protein_codingtolerated(0.08)benign(0.073)TCGA-AN-A0XW-01Breastbreast invasive carcinomaFemale<65III/IVUnknownUnknownSD
SEC24CSNVMissense_Mutationc.3230N>Tp.Ser1077Phep.S1077FP53992protein_codingdeleterious(0)probably_damaging(1)TCGA-AR-A1AK-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyanastrozoleSD
SEC24CSNVMissense_Mutationc.2113N>Ap.Asp705Asnp.D705NP53992protein_codingdeleterious(0)probably_damaging(1)TCGA-BH-A0DH-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapycyclophosphamideSD
SEC24CSNVMissense_Mutationc.1330C>Ap.Arg444Serp.R444SP53992protein_codingdeleterious(0)possibly_damaging(0.495)TCGA-BH-A18G-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
SEC24CSNVMissense_Mutationc.1359N>Gp.Ile453Metp.I453MP53992protein_codingdeleterious(0.01)benign(0.238)TCGA-C8-A12T-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
SEC24CSNVMissense_Mutationc.263N>Gp.Gln88Argp.Q88RP53992protein_codingdeleterious(0.01)benign(0.165)TCGA-EW-A1IZ-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapytaxotereSD
SEC24CSNVMissense_Mutationrs780721252c.2201N>Ap.Arg734Glnp.R734QP53992protein_codingtolerated(0.36)benign(0.205)TCGA-S3-AA10-01Breastbreast invasive carcinomaFemale>=65I/IIChemotherapycytoxanCR
SEC24CinsertionFrame_Shift_Insrs764652839c.1368_1369insCp.Gln459ProfsTer17p.Q459Pfs*17P53992protein_codingTCGA-A2-A0T2-01Breastbreast invasive carcinomaFemale>=65III/IVChemotherapyxelodaPD
SEC24CinsertionFrame_Shift_Insnovelc.324_325insGGAGAp.Pro109GlyfsTer120p.P109Gfs*120P53992protein_codingTCGA-A8-A07R-01Breastbreast invasive carcinomaFemale>=65III/IVAncillaryzoledronicSD
Page: 1 2 3 4 5 6 7 8 9 10 11 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1